Triple agonist at GLP-1R (appetite suppression), GIPR (insulin sensitization), and GCGR (hepatic lipolysis and energy expenditure)
Common incretin-related effects discussed in the broader GLP-1 and metabolic drug class may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, or abdominal discomfort, but trial observations do not establish safe personal use of a research peptide
Jill Thank you for giving me the opportunity to regain the ability to be healthier once more
Information provided is based on available clinical trial data and research on similar medications
Why choose Second Nature over other medication providers, assuming you're eligible
Targeting Sleep Physiology to Modulate Glymphatic Brain Clearance Timo van Hattem, Lieuwe Verkaar, Elena Krugliakova, Nico Adelhfer, Marcel Zeising, Wilhelmus H